There are only a handful of companies whose sole customer is, in effect, a single entity—the U.S. government—and which nevertheless enjoy such a monopoly that no rival can even compete for their contracts. This is precisely the starting point for understanding the investment story currently unfolding in the U.S. defense industry: a company that is the exclusive supplier of both the new-generation strategic bomber and the land component of the U.S. nuclear triad, yet whose shares trade at a significant discount to conservative estimates of fundamental value.

The story is not without risk. Fixed-price contracts for both programs bring earnings volatility; the B-21 alone triggered a $477 million charge in the first quarter of 2025, and the stock has fallen over 26% from its March 2026 peak. Nevertheless—or perhaps precisely because of this—this is the type of situation where an investor with a longer-term horizon is presented with a rare opportunity to purchase decades of visible cash…